Free PANCE Practice Questions

Renal/Urology PANCE practice questions

10 free, board-style Renal/Urology questions for the PANCE, each with the correct answer and a complete explanation. No email, no account required.

Renal/Urology is 9% of the PANCE content blueprint: NCCPA lists Renal System (5%) and Genitourinary System (4%) separately, and this page covers both. These questions come from the clinician-reviewed FirstPassPA bank. Attempt each one before you reveal the answer.

Question 1RenalMedium
A 35-year-old woman presents with 2 days of dysuria, urinary frequency, urgency, and suprapubic pain. She is afebrile and not pregnant, and has no costovertebral angle tenderness or flank pain. She has no recent antibiotic use, urologic abnormality, or history of multidrug-resistant infection. Urinalysis shows pyuria and positive nitrites. Which of the following is the most appropriate first-line treatment?
  • AAmoxicillin × 7 days
  • BNitrofurantoin × 5 days
  • CCeftriaxone IM × 1 dose
  • DAmoxicillin-clavulanate × 7 days
  • ECiprofloxacin × 3 days
Reveal answer & full explanation
Correct answer: B — Nitrofurantoin × 5 days
  • AAmoxicillin × 7 days
  • BNitrofurantoin × 5 days✓
  • CCeftriaxone IM × 1 dose
  • DAmoxicillin-clavulanate × 7 days
  • ECiprofloxacin × 3 days

Why Nitrofurantoin × 5 days is correct

  • The picture is acute uncomplicated cystitis in a healthy, non-pregnant, afebrile woman with no costovertebral angle tenderness, so there are no features of pyelonephritis or a complicated UTI.
  • Per current IDSA guidance, first-line options are nitrofurantoin monohydrate/macrocrystals for 5 days, trimethoprim-sulfamethoxazole double-strength for 3 days, or fosfomycin as a single 3-g dose.
  • Nitrofurantoin concentrates in the urine, has low collateral resistance, and is an ideal agent for cystitis.

Why the others are wrong

  • Amoxicillin-clavulanate × 7 days — Beta-lactams are second-line for cystitis because of lower efficacy and higher relapse rates; selecting it reflects a right-diagnosis-wrong-step trap.
  • Ciprofloxacin × 3 days — Fluoroquinolones are effective but reserved for more serious infections under antimicrobial stewardship and carry boxed-warning toxicities; buzzword-matching 'UTI equals cipro.'
  • Amoxicillin × 7 days — IDSA advises against empiric amoxicillin or ampicillin for cystitis because of poor efficacy and widespread E. coli resistance; unlike amoxicillin-clavulanate, it has no beta-lactamase inhibitor to overcome that resistance (confusing it with the acceptable second-line beta-lactam).
  • Ceftriaxone IM × 1 dose — a single IM ceftriaxone dose is the gonorrhea regimen, and an initial parenteral dose can begin outpatient pyelonephritis treatment, so dysuria with pyuria can trigger it; but she has uncomplicated cystitis without fever or flank pain, which an oral first-line agent such as nitrofurantoin treats without an injection (confusing cystitis with gonococcal infection or pyelonephritis).
Question 2RenalMedium
A 68-year-old man presents after a single episode of painless gross hematuria. He denies dysuria, flank pain, fever, or trauma and takes no anticoagulants. Vital signs are normal and the physical examination is unremarkable. Urinalysis shows more than 100 red blood cells per high-power field with no casts, no proteinuria, no pyuria, and negative nitrites. Cystoscopy and CT urography are planned. Which of the following is the strongest risk factor for the suspected diagnosis?
  • ASaccharin consumption
  • BFrequent NSAID use
  • CCoffee consumption
  • DRecurrent cystitis
  • ECigarette smoking
Reveal answer & full explanation
Correct answer: E — Cigarette smoking
  • ASaccharin consumption
  • BFrequent NSAID use
  • CCoffee consumption
  • DRecurrent cystitis
  • ECigarette smoking✓

Why Cigarette smoking is correct

  • Painless gross hematuria in an older adult with no infection, casts, or proteinuria is urothelial (bladder) carcinoma until proven otherwise, prompting cystoscopy and CT urography.
  • Cigarette smoking is the single strongest and most prevalent modifiable risk factor, accounting for roughly half of all urothelial bladder cancers through excreted aromatic-amine and polycyclic-hydrocarbon carcinogens.
  • Risk is dose-dependent and declines but does not normalize after cessation.

Why the others are wrong

  • Coffee consumption — Any epidemiologic association is weak and largely confounded by smoking; it is not an established strong risk factor (weak-association trap).
  • Recurrent cystitis — Chronic bladder inflammation predisposes mainly to squamous cell carcinoma and is a far weaker contributor than smoking to the urothelial cancer suspected here (confused-with-subtype trap).
  • Frequent NSAID use — Historic phenacetin-containing analgesics were linked to urothelial cancer, but routine modern NSAID use is not a strong risk factor (anchoring on an outdated analgesic association).
  • Saccharin consumption — saccharin caused bladder tumors in rats in the 1970s and once carried a US warning label, but the mechanism is specific to rat urine chemistry and human studies have not shown a meaningful increase in risk; it was removed from the federal carcinogen list in 2000 (outdated-animal-data trap).
Question 3RenalMedium
A 63-year-old man with type 2 diabetes and chronic kidney disease returns for follow-up. His eGFR has been stable at 35 mL/min/1.73 m^2, and his urine albumin-to-creatinine ratio is 560 mg/g. For the past 6 months he has taken lisinopril 40 mg daily (his maximum tolerated dose), empagliflozin 10 mg daily, and metformin 500 mg twice daily, with good adherence. His hemoglobin A1c is 8.4%, and his individualized A1c goal is below 7%. Which of the following is the most appropriate change to his glucose-lowering regimen?
  • AIncrease metformin to 1000 mg twice daily
  • BAdd semaglutide 0.25 mg injected weekly
  • CIncrease empagliflozin to 25 mg once daily
  • DAdd glyburide 5 mg orally once daily
  • EAdd linagliptin 5 mg orally once daily
Reveal answer & full explanation
Correct answer: B — Add semaglutide 0.25 mg injected weekly
  • AIncrease metformin to 1000 mg twice daily
  • BAdd semaglutide 0.25 mg injected weekly✓
  • CIncrease empagliflozin to 25 mg once daily
  • DAdd glyburide 5 mg orally once daily
  • EAdd linagliptin 5 mg orally once daily

Why Add semaglutide 0.25 mg injected weekly is correct

  • He has diabetic kidney disease with severely increased albuminuria (eGFR 35, UACR 560 mg/g) and already takes the kidney-protective foundation, a maximum-tolerated ACE inhibitor plus an SGLT2 inhibitor, with metformin at its renal dose ceiling, yet his A1c is 8.4% against a goal below 7%.
  • KDIGO diabetes-in-CKD guidance recommends a long-acting GLP-1 receptor agonist with proven benefit when metformin plus an SGLT2 inhibitor does not reach the glycemic target, and the ADA Standards of Care recommend a GLP-1 RA with demonstrated benefit in type 2 diabetes with CKD to reduce cardiovascular and kidney outcomes.
  • In the FLOW trial (type 2 diabetes, eGFR 25-75, albuminuria), semaglutide 1 mg weekly lowered the composite of kidney failure, a sustained eGFR decline of 50% or more, or kidney or cardiovascular death by about 24%, and also reduced major cardiovascular events and all-cause death; the FDA added this kidney indication in 2025.
  • 0.25 mg weekly is the labeled starting dose, titrated toward the 1 mg dose studied in FLOW; its A1c-lowering effect does not depend on eGFR, it needs no renal dose adjustment, and it causes little hypoglycemia unless combined with insulin or a sulfonylurea, so it meets his glycemic need and adds organ protection on top of what he already takes.

Why the others are wrong

  • Increase empagliflozin to 25 mg once daily - SGLT2 inhibitors lower glucose by blocking reabsorption of filtered glucose, so the glycemic effect shrinks once eGFR falls below 45; at eGFR 35 the higher dose adds little A1c reduction, and the kidney protection is already delivered at 10 mg, the dose used in EMPA-KIDNEY (the trap is intensifying the drug he already takes).
  • Add linagliptin 5 mg orally once daily - it needs no renal dose adjustment, which makes it look tailor-made for CKD, but DPP-4 inhibitors lower A1c only modestly and were neutral for cardiovascular and kidney outcomes in CARMELINA, so they add glucose lowering without organ protection (the trap is equating renally safe with renally protective).
  • Increase metformin to 1000 mg twice daily - metformin is renally cleared, and at eGFR 30-44 the dose is capped at about 1000 mg per day, which he already takes; doubling it risks drug accumulation and lactic acidosis, and metformin is stopped below eGFR 30 (the trap is treating eGFR 30 as the only metformin threshold).
  • Add glyburide 5 mg orally once daily - a sulfonylurea is inexpensive and lowers A1c considerably, but glyburide is converted in the liver to active metabolites that are renally excreted and accumulate at eGFR 35, causing prolonged hypoglycemia, and sulfonylureas add no cardiovascular or kidney protection (the trap is reaching for a cheap, potent glucose-lowerer without checking renal clearance).

Additional high-yield points

  • Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, is the next kidney-protective add-on when albuminuria of 30 mg/g or more persists on maximum tolerated RAS blockade with eGFR 25 or higher and normal potassium; it does not lower glucose, so it does not answer an above-goal A1c, but it can be added alongside the GLP-1 RA.
  • KDIGO layers therapy in type 2 diabetes with CKD: an ACE inhibitor or ARB for albuminuria with hypertension, metformin if eGFR is 30 or higher, an SGLT2 inhibitor if eGFR is 20 or higher, a GLP-1 RA when glycemic targets are unmet, and finerenone for residual albuminuria.
  • Increase semaglutide at 4-week intervals (0.5 mg, then 1 mg) to limit nausea and vomiting, because GI volume loss can cause prerenal AKI in a patient taking an ACE inhibitor and an SGLT2 inhibitor; avoid it with a personal or family history of medullary thyroid carcinoma or MEN2, and do not combine it with a DPP-4 inhibitor.
  • Sulfonylureas and insulin lower A1c but carry a hypoglycemia risk that rises as eGFR falls; if a sulfonylurea is needed in CKD, glipizide is preferred over glyburide.
Question 4RenalMedium
A 55-year-old man presents with several months of intermittent gross hematuria and dull left flank pain. Exam reveals a firm, palpable mass in the left flank. CT of the abdomen and pelvis shows a 7-cm enhancing heterogeneous mass arising from the left kidney without evidence of metastatic disease. Renal function is normal. Which of the following is the most appropriate next step in management?
  • ATyrosine kinase inhibitor therapy
  • BObservation with serial imaging
  • CSurgical nephrectomy
  • DPercutaneous cryoablation
  • EPercutaneous renal biopsy
Reveal answer & full explanation
Correct answer: C — Surgical nephrectomy
  • ATyrosine kinase inhibitor therapy
  • BObservation with serial imaging
  • CSurgical nephrectomy✓
  • DPercutaneous cryoablation
  • EPercutaneous renal biopsy

Why Surgical nephrectomy is correct

  • Renal cell carcinoma (RCC) classic triad — hematuria, flank pain, and palpable mass — indicates advanced disease
  • CT enhancement confirms malignancy; biopsy is not routinely required preoperatively
  • For masses >4 cm, partial or radical nephrectomy is indicated; partial nephrectomy is preferred when feasible to preserve renal function
  • This patient has a 7-cm mass with no evidence of metastatic disease and normal renal function, making surgical resection the appropriate next step

Why the others are wrong

  • Percutaneous renal biopsy — not routinely required before surgery when CT enhancement is diagnostic for RCC
  • Tyrosine kinase inhibitor therapy — sunitinib and pazopanib (vascular endothelial growth factor receptor (VEGFR) inhibitors) and checkpoint inhibitors (nivolumab + ipilimumab) are used for metastatic RCC, not localized disease
  • Observation with serial imaging — not appropriate for a 7-cm enhancing renal mass without metastases in a surgical candidate
  • Percutaneous cryoablation — ablation is tempting as a minimally invasive nephron-sparing option, but it is used mainly for small cT1a masses, especially in patients who are poor surgical candidates (the AUA advises considering thermal ablation for masses under 3 cm), because local recurrence rises with tumor size; a 7-cm enhancing mass in a surgical candidate warrants nephrectomy
Question 5RenalMedium
A 34-year-old man with nephrotic syndrome due to membranous nephropathy presents to the ED with acute left flank pain and gross hematuria. Vitals: BP 138/86 mm Hg, HR 102/min, T 37.2°C. Exam shows pitting edema and left costovertebral angle tenderness. Labs: Cr 1.9 mg/dL (baseline 1.0), urine protein:creatinine 8.2, LDH elevated. Urinalysis shows RBCs and 4+ protein. Which of the following is the most appropriate imaging test to confirm the suspected diagnosis?
  • ANoncontrast CT of abdomen and pelvis
  • BRenal ultrasound with grayscale imaging
  • CTechnetium-99m MAG3 renal scintigraphy
  • DPlain abdominal radiograph
  • ECT angiography of the renal vessels
Reveal answer & full explanation
Correct answer: E — CT angiography of the renal vessels
  • ANoncontrast CT of abdomen and pelvis
  • BRenal ultrasound with grayscale imaging
  • CTechnetium-99m MAG3 renal scintigraphy
  • DPlain abdominal radiograph
  • ECT angiography of the renal vessels✓

Why CT angiography of the renal vessels is correct

  • This patient has nephrotic syndrome complicated by acute flank pain, hematuria, AKI, and elevated LDH — the textbook presentation of renal vein thrombosis (RVT)
  • CT angiography (or CT venography) of the renal vessels is the diagnostic test of choice, showing a filling defect in the renal vein with high sensitivity and specificity
  • MR venography is an alternative when contrast is contraindicated
  • Treatment is anticoagulation

Why the others are wrong

  • Technetium-99m MAG3 renal scintigraphy — assesses renal perfusion, split function, and drainage; it may show reduced uptake in the affected kidney but cannot visualize the renal vein or demonstrate a thrombus, so it cannot confirm renal vein thrombosis
  • Plain abdominal radiograph — cannot evaluate vascular structures or detect a thrombus; buzzword-matching on flank pain toward a stone series misses that the picture is a hypercoagulable venous event
  • Renal ultrasound with grayscale imaging — grayscale ultrasound has poor sensitivity for renal vein thrombosis and cannot confirm it; this is the anchoring trap of reaching for first-line renal imaging instead of the cross-sectional study that actually visualizes a venous filling defect
  • Noncontrast CT of abdomen and pelvis — flank pain with hematuria triggers the kidney-stone reflex, and noncontrast CT is the right study for a suspected stone; but without IV contrast the renal vein is not opacified, so a venous filling defect cannot be demonstrated and renal vein thrombosis cannot be confirmed

Additional high-yield points

  • Membranous nephropathy carries the highest RVT risk among nephrotic syndromes due to urinary loss of antithrombin III and other anticoagulant factors, creating a hypercoagulable state
Question 6RenalMedium
A 50-year-old man presents to the ED with sudden-onset severe left flank pain radiating to the groin, accompanied by nausea and vomiting. He reports gross hematuria. Vital signs are stable. Urinalysis shows microscopic and gross hematuria without pyuria. Non-contrast CT demonstrates a 6-mm stone in the left distal ureter with mild ipsilateral hydronephrosis and no evidence of infection. Which of the following is the most appropriate initial management?
  • AMedical expulsive therapy
  • BAggressive intravenous hydration
  • CPercutaneous nephrostomy
  • DImmediate ureteroscopy
  • EExtracorporeal shock wave lithotripsy
Reveal answer & full explanation
Correct answer: A — Medical expulsive therapy
  • AMedical expulsive therapy✓
  • BAggressive intravenous hydration
  • CPercutaneous nephrostomy
  • DImmediate ureteroscopy
  • EExtracorporeal shock wave lithotripsy

Why Medical expulsive therapy is correct

  • Ureteral stone 5–10 mm: only about 47–60% pass spontaneously
  • Medical expulsive therapy (MET): tamsulosin (alpha-1 blocker) relaxes ureteral smooth muscle, improves stone passage rate, and reduces analgesic need
  • AUA guideline: offer alpha-blocker MET for uncomplicated distal ureteral stones ≤10 mm; EAU 2026 strongly recommends it for distal stones 5–10 mm, where the benefit is concentrated; evidence of benefit is weaker for proximal ureteral stones
  • NSAIDs (nonsteroidal anti-inflammatory drugs) are superior to opioids for ureteral colic pain

Why the others are wrong

  • Extracorporeal shock wave lithotripsy — a definitive procedure for stones that fail to pass or are larger, not first-line for a small stone likely to pass with MET
  • Percutaneous nephrostomy — reserved for an obstructing stone with infection/sepsis or acute kidney injury, neither present here
  • Immediate ureteroscopy — invasive intervention reserved for failed conservative therapy or larger/refractory stones; with infection or sepsis, the obstructed system is decompressed first and definitive ureteroscopy is deferred
  • Aggressive intravenous hydration — flushing the stone out with large fluid volumes is an intuitive reflex, especially in a patient who is vomiting, but high-volume hydration or forced diuresis has not been shown to speed ureteral stone passage or relieve colic; fluids replace losses as needed, while an alpha-blocker is what improves passage of a 6-mm distal stone

Additional high-yield points

  • Indications for urgent urology referral: obstruction plus infection (fever), solitary kidney, renal failure, intractable pain/vomiting, or bilateral obstructing stones; a stone >10 mm or one that fails to pass with observation/MET warrants elective (not urgent) urologic intervention
Question 7RenalMedium
A 25-year-old man presents with one day of painless gross hematuria that began the same day he developed a sore throat and rhinorrhea. He has had two similar episodes in the past two years, each coinciding with an upper respiratory infection. Exam is unremarkable. Labs show creatinine 1.4 mg/dL and proteinuria 1.5 g/day. Urinalysis shows dysmorphic RBCs. Which of the following is the most likely diagnosis?
  • AGranulomatosis with polyangiitis
  • BThin basement membrane disease
  • CIgA nephropathy
  • DAlport syndrome
  • EPost-streptococcal glomerulonephritis
Reveal answer & full explanation
Correct answer: C — IgA nephropathy
  • AGranulomatosis with polyangiitis
  • BThin basement membrane disease
  • CIgA nephropathy✓
  • DAlport syndrome
  • EPost-streptococcal glomerulonephritis

Why IgA nephropathy is correct

  • IgA nephropathy is the most common primary glomerulonephritis (GN) worldwide
  • KEY DISTINGUISHING FEATURE: synpharyngitic hematuria — gross hematuria occurs concurrent with or within days of a URI, NOT weeks later
  • Diagnosis is confirmed by kidney biopsy showing mesangial IgA deposits on immunofluorescence
  • Treatment (KDIGO 2025): an ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) titrated to the maximum tolerated dose, aiming for proteinuria <0.5 g/day and ideally <0.3 g/day; rapidly progressive (crescentic) disease is treated like ANCA vasculitis with glucocorticoids plus cyclophosphamide

Why the others are wrong

  • Post-streptococcal glomerulonephritis — hematuria follows strep throat by about 1–3 weeks (typically about 10 days) or strep impetigo by 3–6 weeks, not concurrent with the URI
  • Thin basement membrane disease — benign familial hematuria causes persistent MICROSCOPIC hematuria with normal creatinine and no significant proteinuria, and biopsy shows a thinned GBM without IgA
  • Alport syndrome — hereditary (usually X-linked) collagen IV disease with sensorineural hearing loss and ocular defects; biopsy shows basket-weave GBM splitting, not mesangial IgA
  • Granulomatosis with polyangiitis — upper-airway symptoms with glomerular hematuria and an elevated creatinine can suggest this ANCA vasculitis, but GPA causes persistent sinonasal disease (chronic sinusitis, epistaxis, nasal crusting), often lung nodules, and a progressive pauci-immune crescentic GN, not brief bouts of gross hematuria that recur with each viral URI
Question 8RenalMedium
A 45-year-old man presents with 3 weeks of progressive lower extremity edema and frothy urine. He has a history of treated Hodgkin lymphoma 10 years ago, currently in remission. Exam shows periorbital and pitting lower extremity edema. Labs: albumin 2.1 g/dL, total cholesterol 320 mg/dL, creatinine 0.9 mg/dL. Urinalysis shows 4+ protein and no RBCs or casts. 24-hour urine protein is 6.2 g. Renal biopsy on light microscopy shows normal-appearing glomeruli; electron microscopy reveals diffuse foot process effacement without electron-dense deposits. Which of the following is the most likely diagnosis?
  • ARenal amyloidosis
  • BFocal segmental glomerulosclerosis
  • CMinimal change disease
  • DIgA nephropathy
  • EMembranous nephropathy
Reveal answer & full explanation
Correct answer: C — Minimal change disease
  • ARenal amyloidosis
  • BFocal segmental glomerulosclerosis
  • CMinimal change disease✓
  • DIgA nephropathy
  • EMembranous nephropathy

Why Minimal change disease is correct

  • Minimal change disease (MCD) is the most common nephrotic syndrome in children
  • In adults, MCD is associated with NSAIDs (nonsteroidal anti-inflammatory drugs), lithium, and paraneoplastic causes — classically Hodgkin's lymphoma, where T-cell dysfunction causes podocyte damage
  • No hematuria or red cell casts (distinguishes MCD from nephritic syndromes)
  • Electron microscopy shows diffuse podocyte foot process effacement; light microscopy shows normal-appearing glomeruli
  • Treatment: oral corticosteroids; 90% remission in children; adults have good response but more relapses

Why the others are wrong

  • IgA nephropathy — a nephritic process with hematuria and dysmorphic RBCs or red cell casts; this patient has bland urine with no RBCs, and EM shows foot-process effacement without IgA deposits
  • Focal segmental glomerulosclerosis — the key mimic, but it shows segmental sclerosis on light microscopy and is often steroid-resistant, whereas light microscopy here is normal
  • Membranous nephropathy — a leading cause of adult nephrotic syndrome with a paraneoplastic link (usually solid tumors such as lung, colon, or breast cancer), but it is defined by subepithelial electron-dense deposits on electron microscopy (with basement membrane thickening and spikes on light microscopy once established), whereas no deposits are seen here
  • Renal amyloidosis — nephrotic-range proteinuria in a patient with prior Hodgkin lymphoma can suggest secondary (AA) amyloidosis, but amyloid appears as amorphous Congo red-positive material (apple-green birefringence) on light microscopy and as randomly arranged nonbranching fibrils on electron microscopy; here light microscopy is normal and no deposits are seen
Question 9RenalMedium
A 67-year-old man with end-stage renal disease on hemodialysis presents with generalized weakness after missing dialysis. Blood pressure is 88/60 mm Hg and he appears ill. The ECG shows peaked T waves, a widened QRS of 160 ms, and a sine-wave pattern. Serum potassium is 7.8 mEq/L. Which of the following is the most appropriate immediate treatment?
  • AIV sodium bicarbonate
  • BOral sodium polystyrene sulfonate
  • CIV calcium gluconate
  • DIV amiodarone
  • EIV furosemide
Reveal answer & full explanation
Correct answer: C — IV calcium gluconate
  • AIV sodium bicarbonate
  • BOral sodium polystyrene sulfonate
  • CIV calcium gluconate✓
  • DIV amiodarone
  • EIV furosemide

Why IV calcium gluconate is correct

  • Severe hyperkalemia (potassium 7.8 mEq/L) with a sine-wave QRS and a widened complex represents peri-arrest cardiac membrane instability that demands immediate stabilization.
  • IV calcium gluconate antagonizes the membrane effects of hyperkalemia within minutes, restoring the resting membrane potential gradient and preventing degeneration into ventricular fibrillation or asystole.
  • It does not lower the serum potassium; it buys time while potassium-shifting and potassium-removing therapies are started.
  • In an end-stage renal disease patient, emergent hemodialysis is the definitive step once the membrane is stabilized.

Why the others are wrong

  • IV sodium bicarbonate — shifts potassium intracellularly but acts over 15-30 minutes and is unreliable in dialysis-dependent patients; choosing it first is right-problem-wrong-step, addressing the level before stabilizing the membrane.
  • Oral sodium polystyrene sulfonate — removes potassium through the gut over hours, far too slow for a peri-arrest rhythm; a buzzword-match to 'lower the potassium' that ignores the time course.
  • IV furosemide — promotes renal potassium excretion, but an anuric end-stage renal disease patient cannot respond, making it ineffective (premature closure on a reflexive diuretic).
  • IV amiodarone — the wide-complex sine-wave pattern can be mistaken for ventricular tachycardia, but it reflects hyperkalemic depolarization of the cardiac membrane; amiodarone does not reverse that effect, and its conduction-slowing and hypotensive effects are dangerous in a patient whose blood pressure is already 88/60 mm Hg (anchoring on the rhythm instead of the potassium).
Question 10RenalMedium
A 35-year-old woman has hematuria, red blood cell casts, and 3+ proteinuria. Serum creatinine is 2.8 mg/dL, C3 and C4 are low, antinuclear antibody is 1:1280, and anti-double-stranded DNA antibody is positive. Renal biopsy shows endocapillary proliferation involving 80% of glomeruli, subendothelial immune deposits, and 'full-house' immunofluorescence (IgG, IgM, IgA, C3, C1q). Which of the following is the most likely diagnosis?
  • APost-streptococcal glomerulonephritis
  • BMembranoproliferative glomerulonephritis type I
  • CLupus nephritis class IV
  • DLupus nephritis class III
  • ELupus nephritis class V
Reveal answer & full explanation
Correct answer: C — Lupus nephritis class IV
  • APost-streptococcal glomerulonephritis
  • BMembranoproliferative glomerulonephritis type I
  • CLupus nephritis class IV✓
  • DLupus nephritis class III
  • ELupus nephritis class V

Why Lupus nephritis class IV is correct

  • Full-house immunofluorescence (IgG, IgM, IgA, C3, C1q) is characteristic of lupus nephritis.
  • Positive anti-double-stranded DNA with low C3 and C4 indicates active systemic lupus erythematosus with immune-complex consumption.
  • Endocapillary proliferation involving 50% or more of glomeruli, typically with subendothelial immune deposits, defines diffuse lupus nephritis (ISN/RPS class IV); 80% of glomeruli are involved here.
  • Diffuse proliferative (class IV) is the most common and most severe class; the active sediment (RBC casts, heavy proteinuria) and elevated creatinine fit it.

Why the others are wrong

  • Membranoproliferative glomerulonephritis type I - also lowers complement (buzzword trap), but lacks full-house immunofluorescence and is not associated with anti-double-stranded DNA or lupus serologies.
  • Lupus nephritis class V - membranous lupus nephritis is defined by subepithelial deposits with glomerular basement membrane thickening and usually presents as nephrotic syndrome with a relatively bland sediment; pure class V lacks the endocapillary proliferation and subendothelial deposits seen here and seldom produces red cell casts.
  • Post-streptococcal glomerulonephritis - depresses C3 (not typically C4), follows a streptococcal infection, and lacks anti-double-stranded DNA and full-house staining (anchoring on low complement).
  • Lupus nephritis class III - focal lupus nephritis can show the same endocapillary proliferation and subendothelial deposits, but by ISN/RPS definition it involves fewer than 50% of glomeruli; with 80% involved, this is diffuse disease (focal-versus-diffuse threshold trap).

That's 10 of 7,700+. Get the rest.

Unlock the full FirstPassPA bank: 7,700+ board-style questions across every organ system, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.

Start your 7-day free trial → See today's free PANCE question →

Renal/Urology PANCE practice: FAQ

Are these Renal/Urology PANCE practice questions free?

Yes. Each question shows the full vignette, the correct answer, and a complete explanation, with no email or account required. A free 7-day trial unlocks the full 7,700+ question bank, flashcards, and an AI tutor.

How much of the PANCE is Renal/Urology?

Renal/Urology makes up 9% of the PANCE content blueprint (NCCPA's Renal System, 5%, plus Genitourinary System, 4%). FirstPassPA's timed PANCE exams are dealt to the same weights, so a practice exam carries the same share of Renal/Urology questions.

How should I use these questions?

Attempt each vignette before you reveal the answer, then read the full explanation even when you got it right: the reasons each wrong choice is wrong are where most of the learning is. When you are ready for more, practice Renal/Urology questions in the app, or take a full timed PANCE practice exam dealt to the blueprint weights.

Educational use only. These questions are a study aid for PA students and are not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.